Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer
CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.
You may also be interested in...
Actelion's M&A deal with J&J vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the Swiss firm with his wife Martine and friends in 1997, and positions him for another shot at biotech success.
Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.
Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.